HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lebtahi, R. Articles by Crestani, B. Search for Related Content PubMed PubMed Citation Articles by Lebtahi, R. Articles by Crestani, B.

Increased Uptake of ¹¹¹In-Octreotide in Idiopathic Pulmonary Fibrosis

¹ Department of Nuclear Medicine, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; ² Department of Pneumology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; ³ Department of Radiology, Hôpital Bichat, Assistance Publique-Hôpitaux de Paris, Paris, France; ⁴ INSERM Unit 700, Faculté Xavier Bichat, Université Paris 7 Denis Diderot, Paris, France; ⁵ EA 3512, Faculté Xavier Bichat, Université Paris 7 Denis Diderot, Paris, France; ⁶ Department of Radiology, Hôpital Avicenne, Assistance Publique Hôpitaux de Paris, Université Paris 13, Paris, France; and ⁷ Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, Berne, Switzerland

View larger version (117K): [in a new window]   FIGURE 1.  Octreotide scintigraphy. (A) In patient with carcinoid tumor of digestive tract without lung involvement, no octreotide uptake is seen in lung. (B–E) In 2 patients with IPF, diffuse uptake of 111In-octreotide is seen in both lungs, but extent of CT abnormalities differs (L/B of 2.82 and 2.63 and total CT score of 2.8 and 3 for patient in B and D and patient in C and E, respectively).

View larger version (108K): [in a new window]   FIGURE 2.  Autoradiography from fibrotic lung sample, with enlarged views of boxed areas shown on right. (A) Hematoxylin- and eosin-stained section showing blood vessels (arrowheads). (B) Autoradiogram showing total binding of [125I-Tyr3]octreotide. Medium-sized vessels are clearly labeled (arrowheads). Weak labeling may also be seen in some lymphoid aggregates. (C) Autoradiogram showing strong, nonspecific binding that remains in presence of octreotide (1 µmol/L) in several elements of lung. Bar = 1 mm.

View larger version (13K): [in a new window]   FIGURE 3.  Inhibition of [125I-Tyr11]somatostatin-14 binding to cultured lung fibroblasts from IPF and control patients by somatostatin-14 and octreotide. Fibroblasts were incubated for 1 h at 37°C with [125I-Tyr11]somatostatin-14 alone (0.2 nmol/L, white bars) or in presence of somatostatin-14 (10–6 mol/L, hatched bars) or octreotide (10–6 mol/L, black bars). For each patient, results are expressed as mean ± SEM of 4–6 determinations of bound disintegrations per minute (dpm) normalized to 106 cells. *P < 0.05 vs. [125I-Tyr11]somatostatin alone. **P < 0.01 vs. [125I-Tyr11]somatostatin alone.